
Biosimilars Present Opportunity, Challenge For Developing Countries, UNCTAD Group Says
Biosimilars are a hot topic. Beyond the colossal profits foreseen by some, drawing a lot of interested parties into the game, developing countries mean to play a role in this new frontier. However, biosimilars - close copies of biopharmaceutical products - are difficult and very costly to produce and come as a challenge to the generic industry used to duplicating small molecules. And some warn about differences in regulatory requirements, which could effectively boot developing countries out of the global market.










